• QNZ (EVP4593): Deep Mechanistic Insights for NF-κB Modulatio

  2026-06-02

  Explore how QNZ (EVP4593) enables precise NF-κB pathway modulation for advanced neurodegenerative and anti-inflammatory research. This article uniquely integrates molecular action, protocol considerations, and assay design insights for innovative applications.

• Dihydroethidium (DHE): Precision Probe for Superoxide Detect

  2026-06-02

  Dihydroethidium (DHE), also known as hydroethidine, is a validated fluorescent probe for superoxide anion detection in live cells. Its red fluorescence quantitatively reflects intracellular superoxide, supporting oxidative stress assays and apoptosis research. APExBIO’s C3807 kit offers high purity and reproducible performance for advanced cellular redox studies.

• (-)-Epigallocatechin Gallate: Translational Leverage in Neur

  2026-06-01

  This thought-leadership article explores how (-)-Epigallocatechin gallate (EGCG), the principal green tea catechin, is redefining translational research across oncology, virology, and—importantly—emergent neurodegenerative models. We dissect EGCG’s mechanistic versatility, highlight recent breakthroughs in neuroprotection from Tapuy lees research, and provide strategic guidance for deploying APExBIO’s EGCG in advanced discovery workflows. The piece uniquely bridges cancer chemoprevention, antiviral, and neurotherapeutic domains, with actionable protocol parameters and a forward-looking perspective.

• (-)-Epigallocatechin Gallate: Antiangiogenic Mechanisms in A

  2026-06-01

  Explore the multifaceted mechanisms of (-)-Epigallocatechin gallate (EGCG) as an antiangiogenic and antiviral research compound. This article delivers a unique, assay-focused perspective on EGCG's role in modulating angiogenesis and inflammation, with insights grounded in new translational findings.

• Birinapant (TL32711) in Precision Apoptosis Modulation and C

  2026-05-31

  Explore how Birinapant (TL32711) enables precise modulation of apoptosis in cancer cells and advances chemoradiotherapy sensitivity research. This in-depth analysis uniquely bridges molecular mechanisms, protocol optimization, and translational insights for next-generation oncology studies.

• 4-Phenylbutyric Acid: Enhancing ER Stress & Cell Death Assay

  2026-05-30

  4-Phenylbutyric acid (4-PBA) from APExBIO streamlines ER stress modulation with unmatched purity and solubility, empowering researchers to dissect apoptosis and autophagy with precision. Robust protocols and troubleshooting strategies make it the tool of choice for applied cell stress research and toxicology workflows.

• Novel 14-3-3 Interactors ATG9A and PTOV1 in Cancer Regulatio

  2026-05-29

  This study identifies ATG9A and PTOV1 as previously uncharacterized 14-3-3 binding proteins, uncovering their distinct roles in autophagy and oncogenic stability. By elucidating novel regulatory mechanisms, the research advances our understanding of how 14-3-3 proteins modulate cancer-associated pathways and highlights potential therapeutic targets.

• SIRT1/2 Inhibitor IV (cambinol): Reliable Solutions for Cell

  2026-05-29

  This article provides practical, evidence-based guidance for biomedical researchers using SIRT1/2 Inhibitor IV (cambinol, SKU B6063) in cell viability, proliferation, and cytotoxicity assays. Scenario-driven Q&A blocks address experimental design, protocol optimization, and vendor selection, illustrating how cambinol ensures reproducibility and data integrity across oncology, metabolic, and CNS research.

• Nanoplastics and Cadmium Co-exposure Triggers Apoptosis via

  2026-05-28

  This study reveals that combined exposure to polystyrene nanoplastics and cadmium induces apoptosis in intestinal cells through the IP3R/Ca2+/STAT3 signaling axis. By integrating C. elegans and Caco-2 models, the research clarifies how calcium signaling modulation is central to toxicant-induced cell death, offering mechanistic insight for environmental health risk assessment.

• 3-Deazaneplanocin (DZNep): Epigenetic Modulator for Oncology

  2026-05-28

  3-Deazaneplanocin (DZNep) is a potent epigenetic modulator and S-adenosylhomocysteine hydrolase inhibitor. It induces apoptosis and depletes EZH2 in cancer cells, with defined efficacy in acute myeloid leukemia and hepatocellular carcinoma models. APExBIO offers DZNep (A1905) with standardized protocols for reproducible research.

• Evaluating Anti-Cancer Drug Responses: Insights from In Vitr

  2026-05-27

  Schwartz's dissertation critically distinguishes between proliferative arrest and cell death measurements in in vitro cancer drug studies. By clarifying how different drugs induce growth inhibition and apoptosis with distinct timing and magnitude, the study advances the precision of drug evaluation protocols and supports more reproducible cancer research.

• ARTS-XIAP-p53 Axis: New Insights into Apoptosis Regulation

  2026-05-27

  The referenced study identifies XIAP as a direct E3 ligase for p53, revealing that ARTS and ARTS-mimetic small molecules can elevate p53 levels by promoting XIAP degradation. This mechanistic advance uncovers a novel feedback loop in apoptosis regulation, with implications for targeted cancer therapies.

• CA-074 Cathepsin B Inhibitor: Advancing Necroptosis & Metast

  2026-05-26

  CA-074, a highly selective cathepsin B inhibitor, empowers researchers to dissect cell death and metastasis mechanisms with precision. Its nanomolar potency and low cytotoxicity enable robust workflows in cancer, neurodegeneration, and immune modulation studies.

• Panobinostat (LBH589): New Insights into HDAC Inhibition and

  2026-05-26

  Discover how Panobinostat (LBH589) drives apoptosis in cancer cells through HDAC inhibition and novel RNA Pol II signaling. This article offers a unique, in-depth exploration tailored for advanced epigenetic and multiple myeloma research.

• Antibacterial Use and Resistance in Psychiatric Hospitals Du

  2026-05-25

  This study provides a detailed retrospective analysis of antibacterial drug usage and the profiles of bacterial resistance in a Chinese psychiatric hospital during the 2022 epidemic. The findings highlight both the relatively low antibiotic use and unique resistance patterns, underscoring the need for targeted monitoring and stewardship in psychiatric healthcare settings.

13802 records 1/921 page Next 12345 下5页 Last page